43 citations
,
July 2018 in “Journal of The European Academy of Dermatology and Venereology” This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.
5 citations
,
November 2016 in “Experimental and Therapeutic Medicine” In this study, BeauTop treatment significantly increased hair growth in people with androgenetic alopecia compared to placebo, showing effectiveness without adverse reactions.
33 citations
,
August 2016 in “Indian Journal of Dermatology, Venereology and Leprology” In this study of men with androgenetic alopecia, dutasteride was shown to be more effective than finasteride in increasing hair count and reversing hair miniaturization over 24 weeks, with both treatments displaying similar side effect profiles.
42 citations
,
December 2015 in “International Journal of Clinical Pharmacology and Therapeutics” This study found that applying a novel 0.25% finasteride solution to the scalp can effectively reduce scalp DHT levels in men with androgenetic alopecia, potentially reducing systemic side-effects.
32 citations
,
June 2015 in “Dermatologic Therapy” In this study, finasteride was found to be more effective than 5% minoxidil for treating male androgenetic alopecia in Chinese patients, with combination therapy showing the greatest improvement.
18 citations
,
February 2014 in “PubMed” This article reviews current diagnostic and treatment approaches for androgenetic alopecia but reports no new results, focusing on its progression and medical management options.
97 citations
,
January 2014 in “Journal of The American Academy of Dermatology” This study found that dutasteride increased hair growth and restoration in men with androgenetic alopecia more effectively than finasteride and was well tolerated over 24 weeks.
88 citations
,
January 2013 in “Indian Journal of Dermatology, Venereology and Leprology” This article reviews recent advancements in understanding and treating androgenetic alopecia, focusing on new genetic insights, stem cell roles, and diagnostic tools, without reporting new clinical results.
10 citations
,
October 2010 in “International Journal of Andrology” In this study, co-administration of finasteride with oral testosterone undecanoate in young men with induced hypogonadism had no significant effect on serum testosterone or dihydrotestosterone levels, likely due to TU's unique absorption route.
142 citations
,
August 2007 in “Journal of The American Academy of Dermatology” This study found that a new 5% minoxidil foam formulation significantly increased hair counts and improved hair loss condition in men with androgenetic alopecia over 16 weeks compared to placebo.
99 citations
,
October 2006 in “BMC clinical pharmacology” This preliminary study suggests that finasteride might cause depressive symptoms, indicating the need for cautious prescription in patients at high risk for depression.
62 citations
,
April 2004 in “Expert Opinion on Pharmacotherapy” This article reviews the use of finasteride for treating male pattern hair loss, highlighting its mechanism of action in reducing DHT and noting its safety profile with some common adverse effects.
219 citations
,
March 2004 in “Journal of The American Academy of Dermatology” In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.
1 citations
,
January 2004 in “Expert Opinion on Pharmacotherapy” This paper reviews finasteride's role and efficacy in treating male pattern hair loss, finding significant improvements in hair growth and density with a favorable safety profile, though some side effects were noted.
269 citations
,
August 2002 in “Journal of The American Academy of Dermatology” This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.
123 citations
,
February 2002 in “Journal of The American Academy of Dermatology” Minoxidil can cause skin allergy; use alternative solvents or treatments if allergic.
118 citations
,
April 1998 in “Dermatologic Clinics” This review discusses the advancements in understanding and treating androgenetic alopecia and alopecia areata but reports no clinical findings; the authors emphasize the need for further research on molecular control mechanisms.
23 citations
,
April 1991 in “Journal of The American Academy of Dermatology” Minoxidil solution can cause skin irritation and allergies in some users.